An in silico knockout model for gastrointestinal absorption using a systems pharmacology approach - Development and application for ketones

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Shivva, Vittal ^a   Tucker, Ian G ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYL 3 HYDROXYBUTYRATE; 3 HYDROXYBUTYRIC ACID; CARBOXYLIC ACID; KETONE; UNCLASSIFIED DRUG;

ARTICLE; CATABOLISM; COMPUTER MODEL; CONCENTRATION (PARAMETERS); DIFFUSION; GASTROINTESTINAL ABSORPTION; INTESTINE; MOLECULAR WEIGHT; PHARMACOLOGY; SYSTEMS BIOLOGY; SYSTEMS PHARMACOLOGY;

EID: 84991716257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0163795     Document Type: Article

References (45)

1. Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, Tsinman O, et al. PAMPA - a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci. 2004; 21(4):429-41. doi: 10.1016/j.ejps.2003.10.009 PMID: 14998573
2. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989; 96(3):736-49. doi: 10.1016/0016-5085(89)90897-4 PMID: 2914637
3. Kaplan SA, Cotler S. Use of cannulated everted intestinal sac for serial sampling as a drug absorbability (permeability) screen. J Pharm Sci. 1972; 61(9):1361-5. doi: 10.1002/jps.2600610904 PMID: 5068940
4. Ikegami K, Tagawa K, Narisawa S, Osawa T. Suitability of the cynomolgus monkey as an animal model for drug absorption studies of oral dosage forms from the viewpoint of gastrointestinal physiology. Biol Pharm Bull. 2003; 26(10):1442-7. doi: 10.1248/bpb.26.1442 PMID: 14519952
5. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011; 39(7):1196-202. doi: 10.1124/dmd.111.038075 PMID: 21447733
6. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997; 94(5):2031-5. doi: 10.1073/pnas.94.5.2031 PMID: 9050899
7. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006; 34(4):690-5. doi: 10.1124/dmd.105.008219 PMID: 16434544
8. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006; 23 (8):1675-86. doi: 10.1007/s11095-006-9041-2 PMID: 16841194
9. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001; 50 Suppl 1:S41-67. doi: 10.1016/S0169-409X(01)00179-X PMID: 11576695
10. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab. 2010; 11(9):716-29. doi: 10.2174/138920010794328913 PMID: 21189140
11. Sawamoto T, Haruta S, Kurosaki Y, Higaki K, Kimura T. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J Pharm Pharmacol. 1997; 49(4):450-7. doi: 10.1111/j.2042-7158.1997.tb06823.x PMID: 9232547
12. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill JGF. Ketone bodies, potential therapeutic uses. IUBMB life. 2001; 51(4):241-47. doi: 10.1080/152165401753311780 PMID: 11569918
13. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007; 119 (3):535-43. doi: 10.1542/peds.2006-2447 PMID: 17332207
14. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA. 2000; 97 (10):5440-44. doi: 10.1073/pnas.97.10.5440 PMID: 10805800
15. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012; 63(3):401-08. doi: 10.1016/j.yrtph.2012.04.008 PMID: 22561291
16. Shivva V, Cox PJ, Clarke K, Veech RL, Tucker IG, Duffull SB. The Population Pharmacokinetics of D-beta-hydroxybutyrate Following Administration of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate. Aaps j. 2016; 18(3):678-88. doi: 10.1208/s12248-016-9879-0 PMID: 26893218
17. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. An NIH White Paper, QSP Workshop Group (2011), (2011).
18. Tanos PP, Isbister GK, Lalloo DG, Kirkpatrick CM, Duffull SB. A model for venom-induced consumptive coagulopathy in snake bite. Toxicon. 2008; 52(7):769-80. doi: 10.1016/j.toxicon.2008.08.013 PMID: 18831981
19. Visser SA, de Alwis DP, Kerbusch T, Stone JA, Allerheiligen SR. Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e142. doi: 10.1038/psp.2014.40 PMID: 25338195
20. Michaelis L, Menten ML. Die Kinetik der Invertinwirkung. Biochemische Zeitschrift. 1913; 49:333-69.
21. Gaddum JH. The quantitative effects of antagonistic drugs. J Physiol. 1937; 89:7P-9P.
22. Madsen JL, Larsen NE, Hilsted J, Worning H. Scintigraphic determination of gastrointestinal transit times. A comparison with breath hydrogen and radiologic methods. Scand J Gastroenterol. 1991; 26 (12):1263-71. doi: 10.3109/00365529108998623 PMID: 1763296
23. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos. 1995; 16(5):351-80. doi: 10.1002/bdd.2510160502 PMID: 8527686
24. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10 (7):1093-5. PMID: 8378254
25. Carpenter L, Halestrap AP. The kinetics, substrate and inhibitor specificity of the lactate transporter of Ehrlich-Lettre tumour cells studied with the intracellular pH indicator BCECF. Biochem J. 1994; 304 (Pt 3):751-60. doi: 10.1042/bj3040751 PMID: 7818477
26. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000; 529 Pt 2:285-93. PMID: 11101640
27. Martin PM, Gopal E, Ananth S, Zhuang L, Itagaki S, Prasad BM, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006; 98(1):279-88. doi: 10.1111/j.1471-4159.2006.03878.x PMID: 16805814
28. Jackson VN, Halestrap AP. The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2′,7′-bis(carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem. 1996; 271(2):861-8. doi: 10.1074/jbc.271.2.861 PMID: 8557697
29. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999; 341 (Pt 3):529-35. doi: 10.1042/0264-6021:3410529 PMID: 10417314
30. Shivva V, Cox P, Clarke K, Veech R, Tucker I, Duffull S. A Population Pharmacokinetic Model for D-b-Hydroxybutyrate Following Administration of Ketone Monoester. ACoP5 Supplements - J Pharmacokinet Pharmacodyn. 2014; 41(1):7-101. doi: 10.1208/s12248-016-9879-0 PMID: 26893218
31. Halestrap AP. The monocarboxylate transporter family - Structure and functional characterization. IUBMB life. 2012; 64(1):1-9. doi: 10.1002/iub.573 PMID: 22131303
32. Halestrap AP, Wilson MC. The monocarboxylate transporter family - role and regulation. IUBMB Life. 2012; 64(2):109-19. doi: 10.1002/iub.572 PMID: 22162139
33. Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, et al. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am J Physiol Cell Physiol. 2005; 289(4):C846-C52. doi: 10.1152/ajpcell.00112.2005 PMID: 15901598
34. Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008; 10(1):193-9. doi: 10.1208/s12248-008-9022-y PMID: 18446519
35. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. 1999; 343 Pt 2:281-99. doi: 10.1042/bj3430281 PMID: 10510291
36. Heymann E, Mentlein R. Carboxylesterases-amidases. In: Methods in Enzymology. 77. Academic Press, New York 1981. p. 333-44. doi: 10.1016/B978-0-12-380002-2.50022-1 PMID: 7329311
37. Owen OE, Felig P, Morgan AP, Wahren J, Cahill JGF. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969; 48(3):574-83. doi: 10.1172/JCI106016 PMID: 5773093
38. Desrochers S, Dubreuil P, Brunet J, Jette M, David F, Landau BR, et al. Metabolism of (R,S)-1,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs. Am J Physiol. 1995; 268(4 Pt 1):E660-7. PMID: 7733265
39. McGarry JD, Foster DW. Hormonal control of ketogenesis. Biochemical considerations. Arch Intern Med. 1977; 137(4):495-501. doi: 10.1001/archinte.137.4.495 PMID: 403870
40. Meredith D, Christian HC. The SLC16 monocaboxylate transporter family. Xenobiotica. 2008; 38(7-8):1072-106. doi: 10.1080/00498250802010868 PMID: 18668440
41. Balasse EO. Kinetics of ketone body metabolism in fasting humans. Metabolism. 1979; 28(1):41-50. doi: 10.1016/0026-0495(79)90166-5 PMID: 759825
42. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999; 15(6):412-26. doi: 10.1002/(SICI)1520-7560(199911/12)15:6%3C412::AID-DMRR72%3E3.0.CO;2-8 PMID: 10634967
43. Bonate PL. The Art of Modeling. Boston, MA: Springer US; 2011. p. 1-60. doi: 10.1007/978-1-4419-9485-1-1
44. Karlsson MO, Holford N, editors. A tutorial on visual predictive checks. Population Approach Group Europe; 2008; Marseille, France: PAGE.
45. Agoram B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e101. doi: 10.1038/psp.2013.77 PMID: 24552986